U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H46NO4P
Molecular Weight 407.5688
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MILTEFOSINE

SMILES

CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C

InChI

InChIKey=PQLXHQMOHUQAKB-UHFFFAOYSA-N
InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=18472998; http://www.ncbi.nlm.nih.gov/pubmed/?term=11355955; http://www.ncbi.nlm.nih.gov/pubmed/?term=16730362

Miltefosine is an anti-leishmanial agent. It is an alkyl phospholipids compound, was originally intended for breast cancer and other solid tumors. However, it could not be developed as an oral agent because of dose-limiting gastro-intestinal toxicity, and only a topical formulation is approved for skin metastasis. But Miltefosine showed excellent antileishmanial activity both in vitro and in experimental models. Miltefosine is effective in vitro against both promastigotes and amastigotes of various species of Leishmania and also other kinetoplastidae (Trypanosoma cruzi,T. brucei) and other protozoan parasites (Entamoeba histolytica, Acanthamoeba). Mechanism of action is unknown. It is likely to involve interaction with lipids (phospholipids and sterols), including membrane lipids, inhibition of cytochrome c oxidase (mitochondrial function), and apoptosis-like cell death. Miltefosine is approved for the treatment of Visceral leishmaniasis (due to Leishmania donovani), Cutaneous leishmaniasis (due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis) and Mucosal leishmaniasis (due to Leishmania braziliensis).

CNS Activity

Curator's Comment:: Some blood-brain barrier penetration by miltefosine in a human, although with low-level CSF accumulation.

Originator

Curator's Comment:: Discovered by German scientists Hansjorg Eibl, (Max Planck Institute for Biophysical Chemistry), and Clemens Unger ( Gottingen, Germany) miltefosine was prioritized for development in TDR, in partnership with ASTA Medica (now Zentaris), in 1996.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: UNIPROT: B7TYN7 (Cytochrome c oxidase subunit 1)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
IMPAVIDO

Approved Use

Indicated in adults and adolescents ≥12 years of age weighing ≥ 30 kg for the treatment of visceral leishmaniasis caused by Leishmania donovani; Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; Mucosal leishmaniasis caused by Leishmania braziliensis.

Launch Date

1.39518725E12
Curative
IMPAVIDO

Approved Use

Indicated in adults and adolescents ≥12 years of age weighing ≥ 30 kg for the treatment of visceral leishmaniasis caused by Leishmania donovani; Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; Mucosal leishmaniasis caused by Leishmania braziliensis.

Launch Date

1.39518725E12
Curative
IMPAVIDO

Approved Use

Indicated in adults and adolescents ≥12 years of age weighing ≥ 30 kg for the treatment of visceral leishmaniasis caused by Leishmania donovani; Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; Mucosal leishmaniasis caused by Leishmania braziliensis.

Launch Date

1.39518725E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
66.2 μg/mL
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
37.3 μg/mL
50 mg 3 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
636 μg × h/mL
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
295 μg × h/mL
50 mg 3 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.4 day
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.8 day
50 mg 3 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
50 mg 2 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2%
50 mg 3 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MILTEFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
Disc. AE: AST increased, ALT increased...
AEs leading to
discontinuation/dose reduction:
AST increased (0.8%)
ALT increased (0.8%)
Vomiting (0.8%)
Anorexia (0.8%)
Blood urea nitrogen increased (0.8%)
Creatinine increased (0.8%)
Oliguria (0.8%)
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
50 mg 2 times / day multiple, oral
Studied dose
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, at least 12 years of age
n = 299
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Sex: M+F
Population Size: 299
Sources:
Disc. AE: Stevens-Johnson syndrome, Rash...
AEs leading to
discontinuation/dose reduction:
Stevens-Johnson syndrome (0.3%)
Rash (0.3%)
Diarrhea (grade 4, 0.3%)
Hyperbilirubinemia (0.3%)
Thrombocytopenia (0.3%)
Arthritis (0.3%)
Sources:
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources: Page: applications/Miltefosine_application.pdf - p.13
unhealthy, median age of 25 years
n = 89
Health Status: unhealthy
Condition: leishmaniasis
Age Group: median age of 25 years
Sex: M+F
Population Size: 89
Sources: Page: applications/Miltefosine_application.pdf - p.13
Disc. AE: Motion sickness, Headache...
AEs leading to
discontinuation/dose reduction:
Motion sickness (1.1%)
Headache (1.1%)
Sources: Page: applications/Miltefosine_application.pdf - p.13
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources: Page: applications/Miltefosine_application.pdf - p.14
unhealthy, median age of 25 years
n = 89
Health Status: unhealthy
Condition: leishmaniasis
Age Group: median age of 25 years
Sex: M+F
Population Size: 89
Sources: Page: applications/Miltefosine_application.pdf - p.14
Other AEs: Vomiting, Vomiting...
Other AEs:
Vomiting (grade 3-4, 3%)
Vomiting (grade 4-5, 3%)
Sources: Page: applications/Miltefosine_application.pdf - p.14
300 mg 1 times / week multiple, oral
MTD
Dose: 300 mg, 1 times / week
Route: oral
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
unhealthy, median age of 56 years
n = 15
Health Status: unhealthy
Condition: cancer
Age Group: median age of 56 years
Sex: M+F
Population Size: 15
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (grade 3, 6.7%)
Vomiting (grade 3, 6.7%)
Diarrhoea (grade 3, 6.7%)
Sources:
50 mg 3 times / day multiple, oral (mean)
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, median age of 58 years
n = 54
Health Status: unhealthy
Condition: cancer
Age Group: median age of 58 years
Sex: M+F
Population Size: 54
Sources:
DLT: Nausea, Vomiting...
Dose limiting toxicities:
Nausea (grade 1-2)
Vomiting (grade 1-2)
Sources:
AEs

AEs

AESignificanceDosePopulation
ALT increased 0.8%
Disc. AE
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
AST increased 0.8%
Disc. AE
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
Anorexia 0.8%
Disc. AE
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
Blood urea nitrogen increased 0.8%
Disc. AE
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
Creatinine increased 0.8%
Disc. AE
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
Oliguria 0.8%
Disc. AE
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
Vomiting 0.8%
Disc. AE
100 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
unhealthy, at least 12 years of age
n = 120
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Population Size: 120
Sources: Page: nda/2014/204684Orig1s000MedR.pdf - p.159
Arthritis 0.3%
Disc. AE
50 mg 2 times / day multiple, oral
Studied dose
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, at least 12 years of age
n = 299
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Sex: M+F
Population Size: 299
Sources:
Hyperbilirubinemia 0.3%
Disc. AE
50 mg 2 times / day multiple, oral
Studied dose
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, at least 12 years of age
n = 299
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Sex: M+F
Population Size: 299
Sources:
Rash 0.3%
Disc. AE
50 mg 2 times / day multiple, oral
Studied dose
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, at least 12 years of age
n = 299
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Sex: M+F
Population Size: 299
Sources:
Stevens-Johnson syndrome 0.3%
Disc. AE
50 mg 2 times / day multiple, oral
Studied dose
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, at least 12 years of age
n = 299
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Sex: M+F
Population Size: 299
Sources:
Thrombocytopenia 0.3%
Disc. AE
50 mg 2 times / day multiple, oral
Studied dose
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, at least 12 years of age
n = 299
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Sex: M+F
Population Size: 299
Sources:
Diarrhea grade 4, 0.3%
Disc. AE
50 mg 2 times / day multiple, oral
Studied dose
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, at least 12 years of age
n = 299
Health Status: unhealthy
Condition: leishmaniasis
Age Group: at least 12 years of age
Sex: M+F
Population Size: 299
Sources:
Headache 1.1%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources: Page: applications/Miltefosine_application.pdf - p.13
unhealthy, median age of 25 years
n = 89
Health Status: unhealthy
Condition: leishmaniasis
Age Group: median age of 25 years
Sex: M+F
Population Size: 89
Sources: Page: applications/Miltefosine_application.pdf - p.13
Motion sickness 1.1%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources: Page: applications/Miltefosine_application.pdf - p.13
unhealthy, median age of 25 years
n = 89
Health Status: unhealthy
Condition: leishmaniasis
Age Group: median age of 25 years
Sex: M+F
Population Size: 89
Sources: Page: applications/Miltefosine_application.pdf - p.13
Vomiting grade 3-4, 3%
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources: Page: applications/Miltefosine_application.pdf - p.14
unhealthy, median age of 25 years
n = 89
Health Status: unhealthy
Condition: leishmaniasis
Age Group: median age of 25 years
Sex: M+F
Population Size: 89
Sources: Page: applications/Miltefosine_application.pdf - p.14
Vomiting grade 4-5, 3%
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources: Page: applications/Miltefosine_application.pdf - p.14
unhealthy, median age of 25 years
n = 89
Health Status: unhealthy
Condition: leishmaniasis
Age Group: median age of 25 years
Sex: M+F
Population Size: 89
Sources: Page: applications/Miltefosine_application.pdf - p.14
Diarrhoea grade 3, 6.7%
300 mg 1 times / week multiple, oral
MTD
Dose: 300 mg, 1 times / week
Route: oral
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
unhealthy, median age of 56 years
n = 15
Health Status: unhealthy
Condition: cancer
Age Group: median age of 56 years
Sex: M+F
Population Size: 15
Sources:
Nausea grade 3, 6.7%
300 mg 1 times / week multiple, oral
MTD
Dose: 300 mg, 1 times / week
Route: oral
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
unhealthy, median age of 56 years
n = 15
Health Status: unhealthy
Condition: cancer
Age Group: median age of 56 years
Sex: M+F
Population Size: 15
Sources:
Vomiting grade 3, 6.7%
300 mg 1 times / week multiple, oral
MTD
Dose: 300 mg, 1 times / week
Route: oral
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
unhealthy, median age of 56 years
n = 15
Health Status: unhealthy
Condition: cancer
Age Group: median age of 56 years
Sex: M+F
Population Size: 15
Sources:
Nausea grade 1-2
DLT
50 mg 3 times / day multiple, oral (mean)
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, median age of 58 years
n = 54
Health Status: unhealthy
Condition: cancer
Age Group: median age of 58 years
Sex: M+F
Population Size: 54
Sources:
Vomiting grade 1-2
DLT
50 mg 3 times / day multiple, oral (mean)
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, median age of 58 years
n = 54
Health Status: unhealthy
Condition: cancer
Age Group: median age of 58 years
Sex: M+F
Population Size: 54
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies.
1997 Apr 15
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.
2002 Nov
Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.
2006 Feb
In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis.
2006 Feb
Patents

Sample Use Guides

For adults and adolescents ≥12 years of age weighing 30 to 44 kg - one 50 mg capsule twice daily for 28 consecutive days, 45 kg or greater - one 50 mg capsule three times daily for 28 consecutive days. Administer with food to ameliorate gastrointestinal adverse reactions.
Route of Administration: Oral
Miltefosine was tested in vitro against L. donovani promastigotes. The cells death profile was initially slow when concentrations up to 20 mkM were used. Subsequently, a very rapid and dose-dependent death occurred with miltefosine concentrations between 20 and 50 mkM, reaching approximately 100% at around 40 mkM. Approximately 50% death was observed with miltefosine at a concentration of 25 mkM.
Name Type Language
MILTEFOSINE
DASH   INN   MART.   MI   WHO-DD  
INN  
Official Name English
IMPAVIDO
Brand Name English
MILTEFOSINE [MI]
Common Name English
MILTEFOSINE [INN]
Common Name English
D-18506
Code English
HDPC
Common Name English
MILTEFOSINE [ORANGE BOOK]
Common Name English
MILTEFOSINE [MART.]
Common Name English
NSC-758968
Code English
MILTEFOSINE [WHO-DD]
Common Name English
NSC-605583
Code English
Classification Tree Code System Code
NCI_THESAURUS C2188
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.2
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
WHO-VATC QL01XX09
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
FDA ORPHAN DRUG 229406
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
FDA ORPHAN DRUG 540216
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
FDA ORPHAN DRUG 590217
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
NDF-RT N0000190851
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
FDA ORPHAN DRUG 275409
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
EU-Orphan Drug EU/3/05/282
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
WHO-ATC L01XX09
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
FDA ORPHAN DRUG 565016
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
FDA ORPHAN DRUG 565216
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
FDA ORPHAN DRUG 565116
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
Code System Code Type Description
PUBCHEM
3599
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
NCI_THESAURUS
C1170
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
CAS
58066-85-6
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
INN
6362
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
FDA UNII
53EY29W7EC
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
MERCK INDEX
M7549
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1810
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
WIKIPEDIA
Miltefosine
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
MESH
C039128
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
EVMPD
SUB08969MIG
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
DRUG BANK
DB09031
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
RXCUI
1494066
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY RxNorm
EPA CompTox
58066-85-6
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL125
Created by admin on Fri Jun 25 21:50:16 UTC 2021 , Edited by admin on Fri Jun 25 21:50:16 UTC 2021
PRIMARY